Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.505 USD | -2.27% | -0.66% | +31.58% |
May. 30 | NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 | CI |
May. 02 | NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.58% | 43.08M | |
+13.49% | 118B | |
+12.89% | 106B | |
-3.07% | 24.28B | |
+0.84% | 21.96B | |
-9.47% | 18.16B | |
-42.12% | 16.37B | |
-17.91% | 15.56B | |
+4.83% | 13.63B | |
+31.33% | 12.27B |
- Stock Market
- Equities
- NXTC Stock
- News NextCure, Inc.
- NextCure, LegoChem Biosciences to Collaborate on Development of Antibody Drug Conjugates